Abstract

The history of treatment of Hodgkin lymphoma in children and young adults has been one of increasing success, with the focus shifting in recent years from cure, regardless of the cost, to an increasing concern regarding late effects and other consequences of treatment. Ongoing protocols continue to explore the use of risk-based therapy, further delineating the ability to individualize therapy in an effort to decrease morbidity and mortality, while preserving excellent cure rates.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call